

N-chlorosuccinimide, an efficient peptide disulfide bond-forming reagent in aqueous solution†

Cite this: *RSC Advances*, 2013, 3, 14277

Received 4th May 2013,

Accepted 2nd July 2013

DOI: 10.1039/c3ra43149e

www.rsc.org/advances

Tobias M. Postma^{ab} and Fernando Albericio^{*abcd}

A novel method has been developed for the efficient formation of peptide disulfide bonds under aqueous conditions using *N*-chlorosuccinimide. Complete disulfide bond formation is achieved in 15 min with solvent mixtures containing water and acetonitrile.

Disulfide bonds are widespread in peptides and proteins where they strengthen conformation and lead to increased rigidity and proteolytic stability.^{1–3} The number of disulfide-rich therapeutics currently available is increasing, such as the FDA-approved peptide drugs Prialt (ziconotide) and Linzess (linaclotide), both of which contain 3 disulfide bonds.^{4–6} In order to prepare disulfide-rich peptides, efficient disulfide-forming reagents must be used that are compatible with all amino acids, and also preferably with the associated amino acid protecting groups. Many oxidants are used for disulfide bond formation in peptide chemistry (*e.g.* air, DMSO, iodine, thallium salts, mercury salts, and carbon tetrachloride).^{7,8} However, given that there is no universal protocol for the formation of these bonds, this process is empirical and needs to be assessed on a case to case basis. Robust and widely applicable disulfide-forming reagents are required in order to quickly determine the conditions that will allow rapid and quantitative disulfide bond formation with minimal side-reactions.

Recently, we used *N*-chlorosuccinimide (NCS) to form a mixed disulfide between Fmoc-Cys-OH and trimethoxythiophenol under anhydrous conditions.⁹ In comparison to most common oxidants for disulfide formation, NCS is an easy to handle, cheap, and shelf-stable crystalline solid that is soluble in both organic and aqueous solvent mixtures. NCS was found to be an efficient reagent for the formation of mixed cysteine disulfides in organic solvents.

Subsequently, we reported NCS as a highly efficient on-resin disulfide-forming reagent for solid-phase peptide synthesis.¹⁰ Quantitative disulfide formation was achieved in 15 min using 2 equiv. of NCS in DMF, which we demonstrated in the synthesis of several peptides, including an on-resin regioselective synthesis of an α -conotoxin using 2 sequential NCS oxidations (Fig. 1).

Shechter and co-workers reported that NCS is compatible with all amino acids except the oxidation-sensitive Trp and Met.¹¹ However, we found that under our conditions both Trp and Met are compatible with NCS.‡ This finding shows that all amino acids can be used with the NCS method on the solid-phase. In addition, NCS was found to be compatible with the amino acid protecting groups Trt and Mmt, while the common disulfide-forming oxidants such as iodine and thallium salts are not. These results allowed us to conclude that NCS is the most widely applicable disulfide-forming reagent for solid-phase peptide synthesis. However, solid-phase peptide synthesis has several disadvantages




Fig. 1 Regioselective on-resin NCS oxidation.

^aInstitute for Research in Biomedicine, Baldiri Reixac 10, Barcelona, 08028, Spain. E-mail: fernando.albericio@irbbarcelona.org; Fax: +34 93 40 37126; Tel: +34 93 40 37088

^bCIBER-BBN, Barcelona, 08028, Spain

^cDepartment of Organic Chemistry, Martí i Franquès 1, Barcelona, 08028, Spain

^dSchool of Chemistry University of KwaZulu Natal, Durban, 4001, South Africa

† Electronic supplementary information (ESI) available: Detailed experimental procedures, characterization, spectroscopic and chromatographic data. See DOI: 10.1039/c3ra43149e

over solution phase such as: limited scalability and dilution, and generally slower reaction kinetics. For instance, when pseudo-dilution on the solid-phase is not sufficient and leads to intermolecular side-reactions, dilution is not possible and would necessitate resynthesis on a resin with a lower loading. To overcome these disadvantages with the solid-phase NCS method we initiated a study of NCS oxidation in solution. Herein, we report on the formation of peptide disulfide bonds in aqueous solution with NCS. This achievement significantly broadens the applicability of the NCS method.


Our model system was based on the well-studied oxytocin, a nonapeptide currently used as a drug in obstetric medicine to facilitate childbirth.¹² Oxytocin contains one disulfide bond and a C-terminal amide. The peptide was synthesized on the solid-phase using standard Fmoc/*t*Bu chemistry on a Rink Amide resin. The reducing agent-labile protecting group *S*-Tmp was used for the protection of the cysteine thiol.⁹ Prior to cleavage, *S*-Tmp was removed by treatment with dithiothreitol under mildly basic conditions. As a proof of concept for the NCS oxidation of oxytocin under aqueous conditions, experiments were set up using H₂O, and H₂O/acetonitrile mixtures. The fully deprotected peptide was dissolved in H₂O or H₂O/acetonitrile mixtures, and a solution containing 1.5 equiv. of NCS was added. The mixtures were shaken for 15 min at room temperature, lyophilized and subsequently analyzed by chromatographic and spectroscopic techniques. Upon analysis of the reactions, we found that in all cases oxidized oxytocin (**2**) was formed in high purity and all the starting material (**1**) was consumed (Scheme 1).

We next studied the effects of excess NCS on the efficiency of disulfide bond formation in H₂O/acetonitrile. The peptide was dissolved in H₂O/acetonitrile (1 : 1) and 1.1, 1.5 or 2 equiv. of NCS were added. This mixture was then shaken for 15 min, and lyophilized. In all cases, oxidized oxytocin was formed in high purity and no starting material was left (Table 1).

This observation shows that NCS can cleanly form peptide disulfide bonds in an aqueous solution under a wide variety of conditions. Moreover, we observed that an excess of NCS was not detrimental to the purity of the final peptide. The variety of aqueous solvent mixtures and NCS equiv. allows the tailoring of the reaction conditions to the peptide, thus ensuring optimal solubility while retaining highly efficient disulfide bond formation.

To further demonstrate the applicability of aqueous NCS disulfide bond formation, we synthesized the octapeptide octreotate. This compound is a somatostatin analog used for targeting somatostatin receptor-positive tumors, and for radionuclide treatment when conjugated to a radionuclide chelator.^{13,14} Octreotate, contains 1 disulfide bond and 2 D-amino acids (D-Phe and D-Trp). The D-Trp-Lys sequence forms the key β-turn pharmacophore, which causes the high affinity of octreotate for somatostatin receptors.¹⁵

Octreotate was synthesized on a chlorotrityl resin using standard Fmoc/*t*Bu chemistry and subsequently cleaved from the resin. The deprotected peptide was dissolved in H₂O/acetonitrile (1 : 1), a solution containing 1.5 equiv. of NCS was added, and the mixture was shaken for 15 min at room



Scheme 1 Aqueous NCS oxidation of oxytocin.

temperature, lyophilized, and subsequently analyzed. Oxidized cyclic octreotate (**4**) was formed in high purity, and no linear octreotate was present (Scheme 2).

As a final example, we prepared a linear α-conotoxin from a piscivorous conus snail. Oxidative folding of multiple disulfide-containing peptides is widely used for disulfide-rich peptides.^{16,17} However, due to the multiple Cys residues present, several disulfide connectivities can arise, leading to complex mixtures of peptides. The desired disulfide connectivity can be achieved by careful tweaking of the oxidation conditions.¹⁸ In this case, we

Table 1 Results of oxytocin NCS oxidation under distinct conditions

| Oxytocin | H ₂ O/CH ₃ CN | NCS equiv. | Purity (%) ^a |
|------------|-------------------------------------|------------|-------------------------|
| 1 | n/a | n/a | 98 |
| 2-1 | H ₂ O | 1.5 | 88 |
| 2-2 | 1 : 1 | 1.5 | 94 |
| 2-3 | 1 : 3 | 1.5 | 94 |
| 2-4 | 1 : 1 | 1.1 | 94 |
| 2-5 | 1 : 1 | 1.5 | 95 |
| 2-6 | 1 : 1 | 2.0 | 94 |

^a Determined by the peak area of a HPLC chromatogram at 220 nm.

- 2 L. Moroder, H.-J. Musiol, M. Götz and C. Renner, *Biopolymers*, 2005, **80**, 85–97.
- 3 D. P. McGregor, *Curr. Opin. Pharmacol.*, 2008, **8**, 616–619.
- 4 A. P. Bryant, R. W. Busby, W. P. Bartolini, E. A. Cordero, G. Hannig, M. M. Kessler, C. M. Pierce, R. M. Solinga, J. V. Tobin, S. Mahajan-Miklos, M. B. Cohen, C. B. Kurtz and M. G. Currie, *Life Sci.*, 2010, **86**, 760–765.
- 5 E. Dolgin, *Nat. Med.*, 2012, **18**, 1308–1309.
- 6 E. Prommer, *Drugs Today*, 2006, **42**, 369–378.
- 7 K. Akaji and Y. Kiso in *Synthesis of cystine peptides*, in Houben-Weyl: *Methods of Organic Chemistry, Synthesis of Peptides and Peptidominetics*, ed. M. Goodman, A. Felix, L. Moroder and C. Toniolo, Thieme, Stuttgart and New York, 2002, pp. 101–141.
- 8 D. Andreu, F. Albericio, N. A. Sole, M. C. Munson, M. Ferrer and G. Barany, *Methods in Molecular Biology: Peptide Synthesis Protocols*, ed. M. W. Pennington and B. M. Dunn, Humana Press, Inc., Totowa, NJ, 1994, vol. 45, pp. 91–169.
- 9 T. M. Postma, M. Giraud and F. Albericio, *Org. Lett.*, 2012, **14**, 5468–5471.
- 10 T. M. Postma and F. Albericio, *Org. Lett.*, 2013, **15**, 616–619.
- 11 Y. Shechter, A. Patchornik and Y. Burstein, *Biochemistry*, 1976, **15**, 5071–5075.
- 12 C. Viero, I. Shibuya, N. Kitamura, A. Verkhatsky, H. Fujihara, A. Katoh, Y. Ueta, H. H. Zingg, A. Chvatal, E. Sykova and G. Dayanithi, *CNS Neurosci. Ther.*, 2010, **16**, 138–156.
- 13 H.-P. Hsieh, Y.-T. Wu, S.-T. Chen and K.-T. Wang, *Bioorg. Med. Chem.*, 1999, **7**, 1797–1803.
- 14 M. Laznicek, A. Laznickova, H. R. Mäcke, K. Eisenwiener, J. C. Reubi and S. Wenger, *Cancer Biother. Radiopharm.*, 2002, **17**, 527–533.
- 15 J. Gardiner, D. Langenegger, D. Hoyer, A. K. Beck, R. I. Mathad and D. Seebach, *Chem. Biodiversity*, 2008, **5**, 1213–1224.
- 16 E. Fuller, B. R. Green, P. Catlin, O. Buczek, J. S. Nielsen, B. M. Olivera and G. Bulaj, *FEBS J.*, 2005, **272**, 1727–1738.
- 17 N. L. Daly, R. J. Clark and D. J. Craik, *J. Biol. Chem.*, 2003, **278**, 6314–6322.
- 18 T. Kimura in *Synthesis of cystine peptides*, in Houben-Weyl: *Methods of Organic Chemistry, Synthesis of Peptides and Peptidominetics*, ed. M. Goodman, A. Felix, L. Moroder and C. Toniolo, Thieme, Stuttgart and New York, 2002, pp. 142–161.
- 19 A. J. Benie, D. Whitford, B. Hargittai, G. Barany and R. W. Janes, *FEBS Lett.*, 2000, **476**, 287–295.